News for Takeda Pharmaceutical Company Limited (TAK)

Summary Exelixis Inc (EXEL) announced that its partner Ipsen has received approval from the European Commission for CABOMETYX® (cabozantinib) to treat adult pa

[url="]Exelixis, Inc.[/url] (Nasdaq: EXEL) today announced that its partner Ipsen received approval from the European Commission (EC) for CABOMETYX® (cabozant

Cabometyx® is the first and only systemic therapy to be approved in the European Union for previously treated unresectable or metastatic neuroendocrine tumors, regardless of tumor site, grade or previous non-somatostatin analogue-based systemic therapy1,2Approval based on pivotal CABINET Phase III trial which demonstrated a 77% and 62% reduction in the risk of disease progression or death versus placebo in advanced pancreatic and extra-pancreatic neuroendocrine tumors, respectively3,4 PARIS, FRANCE, 24 July 2025 - Ipsen announced today that the European Commission has approved Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues.

Takeda([url="]TSE:4502/NYSE:TAK[/url]) today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for HyHubTM and HyHubTM Du

Takeda Pharmaceutical Company (TAK) receives FDA 510(k) clearance for HyHubTM and HyHubTM Duo devices. The devices are designed to simplify the administ

HyHub and HyHub Duo Reduce the Number of Steps Required to Prepare HYQVIA1 First Devices Customized for a Plasma-Derived Therapy in Takeda’s Broad and Differentia…

Takeda Pharmaceutical Company Limited (NYSE:TAK) is one of the 13 Best Japanese Stocks to Buy According to Hedge Funds. On June 30, Takeda Pharmaceutical Company Limited (NYSE:TAK) announced that it has received US Food and Drug Administration (FDA) approval for AMMAGARD LIQUID ERC with less than or equal to 2 micrograms per milliliter in a […]

Takeda ([url="]TSE:4502/NYSE:TAK[/url]) today announced that all primary and secondary endpoints were met in two Phase 3 randomized, double-blind, placebo-cont

[url=

**media[660110]**

Incyte (Nasdaq:INCY) today announced that data from numerous programs in its hematology/oncology portfolio will be presented at the 2025 European Hematology As

[url="]Takeda[/url] ([url="]TSE:4502/NYSE:TAK[/url]) today announced that the European Commission (EC) approved ADCETRIS® (brentuximab vedotin) in combination

Takeda ([url="]TSE:4502/NYSE:TAK[/url]) today announced that applications are now open for its Innovators in Science Award. This prestigious global award, orig

Takeda (TAK) opens applications for the 2026 Innovators in Science Award, focusing on gastrointestinal and inflammatory diseases, neuroscience, and oncolog

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2025, provided an update on progress toward achieving key corporate obj

Takeda Pharmaceutical Company Limited (NYSE:TAK) Q4 2024 Results Conference Call May 8, 2025 6:00 AM ETCompany ParticipantsChristopher O’Reilly - Head,...

Takeda Pharmaceutical Company Ltd. (TAK) Thursday reported lower net profit in its fiscal 2024, while profit before tax surged from last year with growth in revenues.

\nBioLife Plasma Services, part of Takeda (TSE:4502/NYSE:TAK), today announced that it has begun introducing the new Fresenius Kabi Adaptive Nomogram across its

Takeda Pharmaceutical Company Limited recently awarded $13.8 million to U.S. nonprofits to promote healthy eating and STEM education. The investment und